Most patients — and many prescribers — approach the Wegovy vs Zepbound decision as a simple efficacy comparison. Tirzepatide produces more weight loss on average, therefore tirzepatide. But that logic ignores the cardiovascular outcome data, the mechanistic differences that matter for specific biomarker profiles, and the monitoring requirements that differ between the two. The decision should be made against your lab results.
Mechanism: GLP-1 alone vs dual GLP-1/GIP
Semaglutide (Wegovy) is a pure GLP-1 receptor agonist. It mimics the action of endogenous GLP-1 — reducing appetite, slowing gastric emptying, and stimulating insulin secretion. Tirzepatide (Zepbound) is a dual agonist at both GLP-1 and GIP receptors. GIP receptor activation in adipocytes enhances fat utilization through a distinct pathway. The dual agonism also modulates insulin secretion differently, producing greater beta-cell protection. This mechanistic difference explains much of the divergence in clinical outcomes.
Weight loss data: STEP-1 vs SURMOUNT-1
STEP-1 (68 weeks, patients without diabetes): 14.9% mean body weight loss with semaglutide 2.4mg weekly. SURMOUNT-1 (72 weeks, patients without diabetes): 20.9% mean body weight loss with tirzepatide 15mg weekly. The difference is clinically significant. For a 100kg patient, that is 14.9kg vs 20.9kg of expected weight loss at the maximum dose. Head-to-head indirect comparisons and network meta-analyses consistently favour tirzepatide for weight loss magnitude.
Glycemic control: HbA1c comparison
SURPASS-2 trial (T2D patients): tirzepatide reduced HbA1c by 2.01% vs 1.86% for semaglutide — a statistically and clinically significant difference. Fasting glucose reduction was also greater with tirzepatide. For pre-diabetic patients (HbA1c 5.7–6.4%), tirzepatide's GIP action provides additional beta-cell protection beyond what semaglutide achieves. Patients with significant insulin resistance (HOMA-IR >3.0) show the largest differential benefit.
Cardiovascular outcomes: SELECT trial and beyond
The SELECT trial (2023) was landmark: semaglutide 2.4mg reduced MACE (major adverse cardiovascular events) by 20% in patients with established cardiovascular disease and obesity but without diabetes. This is a primary indication for Wegovy. Tirzepatide's cardiovascular outcome trial (SURMOUNT-MMO) is ongoing. Until it reports, semaglutide has materially stronger cardiovascular evidence for high-risk patients.
Biomarker-based decision framework
Choose semaglutide if: established CVD or 10-year ASCVD risk above 10%, triglycerides below 200 mg/dL, or the primary goal is cardiovascular risk reduction rather than maximum weight loss. Choose tirzepatide if: triglycerides above 200 mg/dL plus low HDL, HbA1c above 6.0% with insulin resistance pattern (HOMA-IR above 2.5), or the primary goal is maximum weight loss with glycemic improvement. Neither medication requires the other to be ruled out — the decision is driven by your risk profile and goals.
Side effect profile differences
Both medications cause nausea, vomiting, and constipation through the same gastric emptying mechanism. Tirzepatide shows slightly higher nausea incidence during early dose escalation weeks but similar long-term GI tolerability. Neither medication has demonstrated meaningful differences in injection site reactions at approved doses. Constipation management (magnesium glycinate, adequate fibre, hydration) applies equally to both. Nausea management protocols — small meals, protein before injection, anti-nausea supplements — are identical.
Monitoring differences on each medication
The same baseline panel is required before starting either medication. On tirzepatide: monitor lipase at 6 weeks given a slightly higher pancreatitis signal in trials. On semaglutide: monitor resting heart rate — a 4–5 bpm increase is documented at therapeutic doses. Both: thyroid panel (TSH) quarterly given the class black-box warning, kidney function panel at each dose escalation, and liver enzymes at 6 months.
Switching considerations
No pharmacologic washout is required when switching from one GLP-1 agonist to another. However, dose titration should be reset to the minimum starting dose of the new medication. Allow 4 weeks at the new minimum before considering escalation. A full metabolic panel at the time of switch is recommended — it establishes the new baseline for tracking response to the second medication.
72 biomarkers. At-home collection. Physician interpretation included. Results in 3–5 days.
Start testing panel →Frequently Asked Questions
Is tirzepatide always better than semaglutide?
Not always. For cardiovascular risk reduction, semaglutide has more mature outcome trial data (SELECT trial). For weight loss magnitude and glycemic control, tirzepatide data is stronger. The right choice depends on your baseline biomarkers and risk profile.
Do I need different testing if I switch from Wegovy to Zepbound?
A baseline panel at switch is recommended. Lipid panel, HbA1c, and liver enzymes are the minimum. A full 72-biomarker panel gives your physician the most complete picture for adjusting your protocol.
Which medication is better for someone with pre-diabetes?
Tirzepatide shows stronger HbA1c reduction in clinical trials. However, your physician should make this decision based on your baseline HbA1c, fasting insulin, and HOMA-IR score.